Pages that link to "Q27010547"

The following pages link to Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review (Q27010547):

Displaying 11 items.

• The therapy of insulin resistance in other diseases besides type 2 diabetes (Q26822399) (← links)
• Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease (Q34647400) (← links)
• miR-149 controls non-alcoholic fatty liver by targeting FGF-21 (Q37117169) (← links)
• Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus (Q38236774) (← links)
• Early to Phase II drugs currently under investigation for the treatment of liver fibrosis (Q38303313) (← links)
• Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion (Q38307168) (← links)
• The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose? (Q41816192) (← links)
• Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway (Q41878667) (← links)
• New medical treatment strategies for nonalcoholic steatohepatitis (Q42175498) (← links)
• Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. (Q55175731) (← links)
• Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease (Q89065358) (← links)